[
  {
    "ts": null,
    "headline": "Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta速 in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025",
    "summary": "SANTA MONICA, Calif., June 01, 2025--Kite, a Gilead Company (Nasdaq: GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta速 (axicabtagene ciloleucel) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) assigned to treatment in an outpatient setting (no planned hospital stay) versus those assigned to an inpatient setting in a hospital. The analysis, based on data collected from the Center for International Blood and Marrow Transplant Researc",
    "url": "https://finnhub.io/api/news?id=da1f2733288be62f41a2270bc15e23589af2023ea44181c6c8f81b4e5e6b262a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748779200,
      "headline": "Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta速 in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025",
      "id": 134927469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SANTA MONICA, Calif., June 01, 2025--Kite, a Gilead Company (Nasdaq: GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta速 (axicabtagene ciloleucel) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) assigned to treatment in an outpatient setting (no planned hospital stay) versus those assigned to an inpatient setting in a hospital. The analysis, based on data collected from the Center for International Blood and Marrow Transplant Researc",
      "url": "https://finnhub.io/api/news?id=da1f2733288be62f41a2270bc15e23589af2023ea44181c6c8f81b4e5e6b262a"
    }
  },
  {
    "ts": null,
    "headline": "Gilead's CAR-T cell therapy shows promise in deadly brain cancer",
    "summary": "A Gilead Sciences-backedtherapy made with a patient's own white blood cells shranktumors in 62% of patients with recurrent glioblastoma, a rareevent for a fatal brain cancer with few treatment...",
    "url": "https://finnhub.io/api/news?id=7d2ab0efe91cfa9a33cffbd93863dfbaf106d58e421c74513d0d475b0da39c8b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748764868,
      "headline": "Gilead's CAR-T cell therapy shows promise in deadly brain cancer",
      "id": 134927094,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "A Gilead Sciences-backedtherapy made with a patient's own white blood cells shranktumors in 62% of patients with recurrent glioblastoma, a rareevent for a fatal brain cancer with few treatment...",
      "url": "https://finnhub.io/api/news?id=7d2ab0efe91cfa9a33cffbd93863dfbaf106d58e421c74513d0d475b0da39c8b"
    }
  }
]